142 related articles for article (PubMed ID: 37456683)
1. Prime Time for HLA Desensitization: Imlifidase in the Spotlight.
Bestard O; Moreso F; Dorling A
Transpl Int; 2023; 36():11616. PubMed ID: 37456683
[No Abstract] [Full Text] [Related]
2. Imlifidase Desensitization in HLA-incompatible Kidney Transplantation: Finding the Sweet Spot.
de Weerd AE; Roelen DL; van de Wetering J; Betjes MGH; Heidt S; Reinders MEJ
Transplantation; 2024 Feb; 108(2):335-345. PubMed ID: 37340532
[TBL] [Abstract][Full Text] [Related]
3. Imlifidase for Kidney Transplantation of Highly Sensitized Patients With a Positive Crossmatch: The French Consensus Guidelines.
Couzi L; Malvezzi P; Amrouche L; Anglicheau D; Blancho G; Caillard S; Freist M; Guidicelli GL; Kamar N; Lefaucheur C; Mariat C; Koenig A; Noble J; Thaunat O; Thierry A; Taupin JL; Bertrand D
Transpl Int; 2023; 36():11244. PubMed ID: 37448448
[TBL] [Abstract][Full Text] [Related]
4. Imlifidase for the treatment of anti-HLA antibody-mediated processes in kidney transplantation.
Huang E; Maldonado AQ; Kjellman C; Jordan SC
Am J Transplant; 2022 Mar; 22(3):691-697. PubMed ID: 34467625
[TBL] [Abstract][Full Text] [Related]
5. Imlifidase therapy: exploring its clinical uses.
Rostaing L; Noble J; Malvezzi P; Jouve T
Expert Opin Pharmacother; 2023 Feb; 24(2):259-265. PubMed ID: 36404277
[TBL] [Abstract][Full Text] [Related]
6. Desensitization in the Setting of HLA-Incompatible Kidney Transplant.
Malvezzi P; Jouve T; Noble J; Rostaing L
Exp Clin Transplant; 2018 Aug; 16(4):367-375. PubMed ID: 29863455
[TBL] [Abstract][Full Text] [Related]
7. First use of imlifidase desensitization in a highly sensitized lung transplant candidate: a case report.
Roux A; Bunel V; Belousova N; Messika J; Tanaka S; Salpin M; Roussel A; Beaumont-Azuar L; Picard C; Brugiere O; Devaquet J; Sage E; Le Guen M; Taupin JL; Devriese M; Glorion M; Parquin F
Am J Transplant; 2023 Feb; 23(2):294-297. PubMed ID: 36695676
[TBL] [Abstract][Full Text] [Related]
8. Pretransplant Desensitization with Costimulation Blockade and Proteasome Inhibitor Reduces DSA and Delays Antibody-Mediated Rejection in Highly Sensitized Nonhuman Primate Kidney Transplant Recipients.
Ezekian B; Schroder PM; Mulvihill MS; Barbas A; Collins B; Freischlag K; Yoon J; Yi JS; Smith F; Olaso D; Saccoccio FM; Permar S; Farris AB; Kwun J; Knechtle SJ
J Am Soc Nephrol; 2019 Dec; 30(12):2399-2411. PubMed ID: 31658991
[TBL] [Abstract][Full Text] [Related]
9. Posttransplant allosensitization in low immunological risk kidney and kidney-pancreas graft recipients.
Malheiro J; Tafulo S; Dias L; Martins LS; Fonseca I; Almeida M; Pedroso S; Freitas F; Beirão I; Castro Henriques A; Cabrita A
Biomed Res Int; 2014; 2014():438945. PubMed ID: 24839605
[TBL] [Abstract][Full Text] [Related]
10. Imlifidase-generated Single-cleaved IgG: Implications for Transplantation.
Bockermann R; Järnum S; Runström A; Lorant T; Winstedt L; Palmqvist N; Kjellman C
Transplantation; 2022 Jul; 106(7):1485-1496. PubMed ID: 34966107
[TBL] [Abstract][Full Text] [Related]
11. A review of imlifidase in solid organ transplantation.
Lonze BE
Expert Opin Biol Ther; 2021 Feb; 21(2):135-143. PubMed ID: 33180664
[TBL] [Abstract][Full Text] [Related]
12. Combination of Total Lymphoid Irradiation, Low-Dose IVIG and ATG as Rescue Therapy for Highly Sensitized and Antibody-Mediated Rejection Renal Transplant Recipients.
Zhu D; Qi G; Tang Q; Li L; Yang C; Lin M; Wu B; Xu M; Cai J; Zhu T; Rong R
Clin Transpl; 2014; ():215-21. PubMed ID: 26281148
[TBL] [Abstract][Full Text] [Related]
13. IgM single antigen bead HLA-assay is affected by imlifidase through the cleavage of IgG but not IgM.
Runström A; Sjöholm K; Roupé KM; Lorant T; Kjellman C; Bockermann R
Transpl Immunol; 2021 Oct; 68():101436. PubMed ID: 34265468
[TBL] [Abstract][Full Text] [Related]
14. [Improving access to kidney transplantation for highly sensitized patients: What place for IL-6 pathway blockade in desensitization protocols?].
Weinhard J; Noble J; Jouve T; Malvezzi P; Rostaing L
Nephrol Ther; 2022 Dec; 18(7):577-583. PubMed ID: 36328901
[TBL] [Abstract][Full Text] [Related]
15. Desensitization in kidney transplantation: review and future perspectives.
Abu Jawdeh BG; Cuffy MC; Alloway RR; Shields AR; Woodle ES
Clin Transplant; 2014 Apr; 28(4):494-507. PubMed ID: 24621089
[TBL] [Abstract][Full Text] [Related]
16. [Kidney Transplant in a Highly Sensitized Patient Treated with Imlifidase].
D'Elia L; Cencioni L; Ciabattini F; D'Argenzio L; Santirosi PV
G Ital Nefrol; 2023 Oct; 40(5):. PubMed ID: 38010248
[TBL] [Abstract][Full Text] [Related]
17. Outcomes at 3 years posttransplant in imlifidase-desensitized kidney transplant patients.
Kjellman C; Maldonado AQ; Sjöholm K; Lonze BE; Montgomery RA; Runström A; Lorant T; Desai NM; Legendre C; Lundgren T; von Zur Mühlen B; Vo AA; Olsson H; Jordan SC
Am J Transplant; 2021 Dec; 21(12):3907-3918. PubMed ID: 34236770
[TBL] [Abstract][Full Text] [Related]
18. Development of de novo HLA donor specific antibodies (HLA-DSA), HLA antibodies (HLA-Ab) and allograft rejection post blood transfusion in kidney transplant recipients.
Jalalonmuhali M; Carroll RP; Tsiopelas E; Clayton P; Coates PT
Hum Immunol; 2020 Jul; 81(7):323-329. PubMed ID: 32327243
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of immunoadsorption to reduce donor-specific alloantibodies in kidney-transplant candidates.
Rostaing L; Congy N; Aarnink A; Maggioni S; Allal A; Sallusto F; Game X; Kamar N
Exp Clin Transplant; 2015 Apr; 13 Suppl 1():201-6. PubMed ID: 25894155
[TBL] [Abstract][Full Text] [Related]
20. Safety, immunogenicity, pharmacokinetics, and efficacy of degradation of anti-HLA antibodies by IdeS (imlifidase) in chronic kidney disease patients.
Lorant T; Bengtsson M; Eich T; Eriksson BM; Winstedt L; Järnum S; Stenberg Y; Robertson AK; Mosén K; Björck L; Bäckman L; Larsson E; Wood K; Tufveson G; Kjellman C
Am J Transplant; 2018 Nov; 18(11):2752-2762. PubMed ID: 29561066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
